Login Register Cart 0
Generic placeholder image

Pharmaceutical Nanotechnology

Editor-in-Chief

ISSN (Print): 2211-7385
ISSN (Online): 2211-7393

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Development of Dioctyl Phthalate@Fe3O4 Nanocomposite Reinforced Hollow Fiber Solid/ Liquid Phase Microextraction Followed by HPLC-DAD for the Determination of Atorvastatin and Gemfibrozil in Human Urine

Author(s): Nabil N. AL-Hashimi *, Majed H. Shtaiwi, Saja H. Hamed , Amjad H. El-Sheikh , Rand O. Shahin, Linda S. Banisakher and Dua'a M. Tahboub

Volume 9, Issue 5, 2021

Published on: 28 December, 2021

Page: [372 - 382] Pages: 11

DOI: 10.2174/2211738510666211222113358

Price: $65

Abstract

Background: The desirable levels of lipids, especially in patients with coronary artery disease, might not be achievable with a single lipid-lowering drug; thus, combination therapy using atorvastatin and gemfibrozil seems to be a promising approach. However, the potential for drugdrug interaction needs to be taken into consideration, and the combination (atorvastatin and gemfibrozil) is recommended only when other options for reducing lipids have been exhausted.

Objectives: Many studies are conducted for the determination of atorvastatin or gemfibrozil in biological fluids and tablets; however, the simultaneous determination of the two drugs in complex biological matrices is limited. Consequently, the development of a sensitive method for simultaneous determination of atorvastatin and gemfibrozil in urine samples is urgently needed to make sure that the doses of both medications are given to patients correctly to prevent the risk of side effects outcomes associated with the adverse drug-drug interaction.

Methods: A synthesized nanocomposite sorbent, dioctyl phthalate coated on the surface of magnetite (DOP@Fe3O4), was reinforced and immobilized into the pores of 2.5 cm segment hollow fiber microtube via ultrasonication, and the lumen of the microtube was filled with 1-octanol as an organic solvent with two ends heat-sealed. The prepared (DOP@Fe3O4-HF-SLPME) device was directly immersed into 10 mL of a sample solution containing atorvastatin and gemfibrozil with agitation. Subsequently, the microextraction device was transferred to HPLC-micro-vial containing an appropriate solvent, and the selected analytes were desorbed under ultrasonication prior to HPLCDAD analysis. The main factors influencing the adsorption and desorption process of the selected drugs have been optimized.

Results: The DOP@Fe3O4-HF-SLPME combined with the HPLC-DAD method was analytically evaluated for the simultaneous determination of atorvastatin and gemfibrozil in human urine samples using the optimized conditions. In spiked urine samples, the method showed a good linearity R2˃ 0.998, RSD from 1.41- 5.33%, and the limits of detection/ quantification (LOD/ LOQ) were 0.11/ 0.36 and 0.73/ 2.42 μg L-1 for atorvastatin and gemfibrozil, respectively. The enrichment factors of atorvastatin and gemfibrozil were 83.4 and 101.2, with extraction recoveries of 80.9% and 99.0%, respectively. The developed method demonstrated comparable results against referenced methods and a satisfactory result for determining the selected drugs in the patient’s urine samples.

Conclusion: The DOP@Fe3O4-HF-SLPME followed by HPLC-DAD was proved to be an efficient, sensitive, and cost-effective biopharmaceutical analysis method for trace levels of atorvastatin and gemfibrozil in the biological fluid matrix.

Keywords: Reinforced hollow fiber solid/ liquid phase microextraction, magnetic nano-iron oxide, atorvastatin, gemfibrozil, HPLC-DAD, urine.

« Previous Next »
Graphical Abstract

[1]
Kračun M, Kocijan A, Bastarda A, Grahek R, Plavec J, Kocjan D. Isolation and structure determination of oxidative degradation products of atorvastatin. J Pharm Biomed 2009; 50(5): 729-36.
[http://dx.doi.org/10.1016/j.jpba.2009.06.008] [PMID: 19615842]
[2]
Golomb BA, Evans MA. Statin adverse effects: a review of the literature and evidence for a mitochondrial mechanism. Am J Cardiovasc Drugs 2008; 8(6): 373-418.
[http://dx.doi.org/10.2165/0129784-200808060-00004] [PMID: 19159124]
[3]
Lea AP, McTavish D. Atorvastatin. A review of its pharmacology and therapeutic potential in the management of hyperlipidaemias. Drugs 1997; 53(5): 828-47.
[http://dx.doi.org/10.2165/00003495-199753050-00011] [PMID: 9129869]
[4]
Croom KF, Plosker GL. Atorvastatin: A review of its use in the primary prevention of cardiovascular events in patients with type 2 diabetes mellitus. Drugs 2005; 65(1): 137-52.
[http://dx.doi.org/10.2165/00003495-200565010-00015] [PMID: 15610062]
[5]
Adhyaru BB, Jacobson TA. Safety and efficacy of statin therapy. Nat Rev Cardiol 2018; 15(12): 757-69.
[http://dx.doi.org/10.1038/s41569-018-0098-5] [PMID: 30375494]
[6]
de Pádua Borges R, Degobi NAH, Bertoluci MC. Choosing statins: a review to guide clinical practice. Arch Endocrinol Metab 2021; 64(6): 639-53.
[PMID: 33166435]
[7]
Angelidi AM, Stambolliu E, Adamopoulou KI, Kousoulis AA. Is atorvastatin associated with new onset diabetes or deterioration of glycemic control? Systematic review using data from 1.9 million patients. Int J Endocrinol 2018; 2018: 8380192.
[http://dx.doi.org/10.1155/2018/8380192] [PMID: 30425742]
[8]
McTaggart F, Jones P. Effects of statins on high-density lipoproteins: a potential contribution to cardiovascular benefit. Cardiovasc Drugs Ther 2008; 22(4): 321-38.
[http://dx.doi.org/10.1007/s10557-008-6113-z] [PMID: 18553127]
[9]
Ginsberg HN. Review: Efficacy and mechanisms of action of statins in the treatment of diabetic dyslipidemia. J Clin Endocrinol Metab 2006; 91(2): 383-92.
[http://dx.doi.org/10.1210/jc.2005-2084] [PMID: 16291700]
[10]
Ray SK, Rege NN. Atorvastatin: in the management of hyperlipidaemia. J Postgrad Med 2000; 46(3): 242-3.
[PMID: 11298482]
[11]
McKenney JM. Pharmacologic characteristics of statins. Clin Cardiol 2003; 26(4)(Suppl. 3): III32-8.
[http://dx.doi.org/10.1002/clc.4960261507] [PMID: 12708637]
[12]
Masana L, Zamora A, Plana N, et al. Incidence of cardiovascular disease in patients with familial hypercholesterolemia phenotype: Analysis of 5 years follow-up of real-world data from more than 1.5 million patients. J Clin Med 2019; 8(7): 1-15.
[http://dx.doi.org/10.3390/jcm8071080] [PMID: 31340450]
[13]
Li M, Wang X, Li X, et al. Statins for the primary prevention of coronary heart disease. BioMed Res Int 2019; 2019: 4870350.
[http://dx.doi.org/10.1155/2019/4870350] [PMID: 30834266]
[14]
Zhou Q, Liao JK. Statins and cardiovascular diseases: From cholesterol lowering to pleiotropy. Curr Pharm Des 2009; 15(5): 467-78.
[http://dx.doi.org/10.2174/138161209787315684] [PMID: 19199975]
[15]
Todd PA, Ward A. Gemfibrozil. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in dyslipidaemia. Drugs 1988; 36(3): 314-39.
[http://dx.doi.org/10.2165/00003495-198836030-00004] [PMID: 3056692]
[16]
Nyman J, Martinson M, Nelson D, et al. Cost-effectiveness of gemfibrozil for coronary heart disease patient with low levels of high-density lipoprotein cholesterol. Arch Intern Med 2002; 162: 177-82.
[http://dx.doi.org/10.1001/archinte.162.2.177] [PMID: 11802751]
[17]
Li W, Jia HY, He XH, Shi WG, Zhong BH. Novel phenoxyalkylcarboxylic acid derivatives as hypolipidaemic agents. J Enzyme Inhib Med Chem 2012; 27(2): 311-8.
[http://dx.doi.org/10.3109/14756366.2011.589840] [PMID: 22085137]
[18]
Shammas NW, Kapalis MJ, Deckert J, et al. Effectiveness of statin-gemfibrozil combination therapy in patients with mixed hyperlipidemia: experience of a community lipid clinic and safety review from the literature. Prev Cardiol 2003; 6(4): 189-94.
[http://dx.doi.org/10.1111/j.1520-037X.2003.02200.x] [PMID: 14605512]
[19]
Wiggins BS, Saseen JJ, Morris PB. Gemfibrozil in combination with statins-is it really contraindicated? Curr Atheroscler Rep 2016; 18(4): 18.
[http://dx.doi.org/10.1007/s11883-016-0571-8] [PMID: 26932225]
[20]
Dalugama C, Pathirage M, Kularatne SAM. Delayed presentation of severe rhabdomyolysis leading to acute kidney injury following atorvastatin-gemfibrozil combination therapy: a case report. J Med Case Reports 2018; 12(1): 143.
[http://dx.doi.org/10.1186/s13256-018-1685-0] [PMID: 29784023]
[21]
Norata GD, Tibolla G, Catapano AL. Statins and skeletal muscles toxicity: From clinical trials to everyday practice. Pharmacol Res 2014; 88: 107-13.
[http://dx.doi.org/10.1016/j.phrs.2014.04.012] [PMID: 24835295]
[22]
Werremeyer A, Koo J, Welch J. A comparison of adverse effects of simvastatin plus gemfibrozil and atorvastatin plus gemfibrozil. Hosp Pharm 2007; 42(7): 631-6.
[http://dx.doi.org/10.1310/hpj4207-631]
[23]
Harper C, Jacobson T. Avoiding statin myopathy: understanding key drug interactions. Clin Lipidol 2011; 6(6): 665-74.
[http://dx.doi.org/10.2217/clp.11.57]
[24]
Whitfield LR, Porcari AR, Alvey C, Abel R, Bullen W, Hartman D. Effect of gemfibrozil and fenofibrate on the pharmacokinetics of atorvastatin. J Clin Pharmacol 2011; 51(3): 378-88.
[http://dx.doi.org/10.1177/0091270010366446] [PMID: 20413454]
[25]
Wägner AM, Jorba O, Bonet R, Ordóñez-Llanos J, Pérez A. Efficacy of atorvastatin and gemfibrozil, alone and in low dose combination, in the treatment of diabetic dyslipidemia. J Clin Endocrinol Metab 2003; 88(7): 3212-7.
[http://dx.doi.org/10.1210/jc.2003-030153] [PMID: 12843167]
[26]
Wiggins BS, Saseen JJ, Page RL II, et al. Recommendations for management of clinically significant drug-drug interactions with statins and select agents used in patients with cardiovascular disease a scientific statement from the American heart association. Circulation 2016; 134(21): e468-95.
[http://dx.doi.org/10.1161/CIR.0000000000000456] [PMID: 27754879]
[27]
Ashfaq M, Khan I, Asghar M. Development and validation of liquid chromatographic method for gemfibrozil and simvastatin in binary combination. J Chil Chem Soc 2008; 53(3): 1617-9.
[http://dx.doi.org/10.4067/S0717-97072008000300015]
[28]
Taheri S, Jalali F, Fattahi N, Bahrami G. Sensitive determination of atorvastatin in human plasma by dispersive liquid-liquid microextraction and solidification of floating organic drop followed by high-performance liquid chromatography. J Sep Sci 2015; 38(2): 309-15.
[http://dx.doi.org/10.1002/jssc.201401115] [PMID: 25382401]
[29]
Vittal S, Shitut NR, Kumar TR, Vinu MC, Mullangi R, Srinivas NR. Simultaneous quantitation of rosuvastatin and gemfibrozil in human plasma by high-performance liquid chromatography and its application to a pharmacokinetic study. Biomed Chromatogr 2006; 20(11): 1252-9.
[http://dx.doi.org/10.1002/bmc.692] [PMID: 16838266]
[30]
Silvia I, Klára K, Daniela-Lucia M. Simultaneous determination of atorvastatin and amlodipine in industrial tablets by apparent content curve and HPLC methods. Acta Med Marisiensis 2013; 2013: 44-8.
[31]
Elsherif Z, Abas S, Abdelwahab M, EL-Weshahy S. Determination of gemfibrozil and fenofibrate in pharmaceuticals in present of their degradation products. Int J Pharm Pharm Sci 2013; 5: 886-96.
[32]
Khan I, Jillani S, Ashfaq M. Determination of atorvastatin and gemfibrozil in human plasma by reversed-phase liquid chromatography. Lat Am Pharm 2010; 29(8): 1383-8.
[33]
Arghavani-Beydokhti S, Rajabi M, Asghari A. Combination of magnetic dispersive micro solid-phase extraction and supramolecular solvent-based microextraction followed by high-performance liquid chromatography for determination of trace amounts of cholesterol-lowering drugs in complicated matrices. Anal Bioanal Chem 2017; 409(18): 4395-407.
[http://dx.doi.org/10.1007/s00216-017-0383-x] [PMID: 28547184]
[34]
Arghavani-Beydokhti S, Asghari A, Bazregar M, Rajabi M. Application of a tandem air-agitated liquid-liquid microextraction technique based on solidification of floating organic droplets as an efficient extraction method for determination of cholesterol-lowering drugs in complicated matrices. RSC Advances 2016; 6: 93582-9.
[http://dx.doi.org/10.1039/C6RA19414A]
[35]
Khan WA, Arain MB, Yamini Y, et al. Hollow fiber-based liquid phase microextraction followed by analytical instrumental techniques for quantitative analysis of heavy metal ions and pharmaceuticals. J Pharm Anal 2020; 10(2): 109-22.
[http://dx.doi.org/10.1016/j.jpha.2019.12.003] [PMID: 32373384]
[36]
Eś’haghi Z, Golsefidi MA, Saify A, Tanha AA, Rezaeifar Z, Alian-Nezhadi Z. Carbon nanotube reinforced hollow fiber solid/liquid phase microextraction: a novel extraction technique for the measurement of caffeic acid in Echinacea purpurea herbal extracts combined with high-performance liquid chromatography. J Chromatogr A 2010; 1217(17): 2768-75.
[http://dx.doi.org/10.1016/j.chroma.2010.02.054] [PMID: 20227700]
[37]
Wu C, Liu Y, Wu Q, Wang C, Wang Z. Combined use of liquid-liquid microextraction and carbon nanotube reinforced hollow fiber microporous membrane solid-phase microextraction for the determination of triazine herbicides in water and milk samples by high-performance liquid chromatography. Food Anal Methods 2012; 5: 540-50.
[http://dx.doi.org/10.1007/s12161-011-9280-7]
[38]
Yang Y, Chen J, Shi Y-P. Determination of diethylstilbestrol in milk using carbon nanotube-reinforced hollow fiber solid-phase microextraction combined with high-performance liquid chromatography. Talanta 2012; 97: 222-8.
[http://dx.doi.org/10.1016/j.talanta.2012.04.021] [PMID: 22841071]
[39]
Sehati N, Dalali N, Soltanpour S, Dorraji MS. Extraction and preconcentration of tylosin from milk samples through functionalized TiO2 nanoparticles reinforced with a hollow fiber membrane as a novel solid/liquid-phase microextraction technique. J Sep Sci 2014; 37(15): 2025-31.
[http://dx.doi.org/10.1002/jssc.201400393] [PMID: 24890459]
[40]
Rezaeifar Z, Eś’haghi Z, Rounaghi GH, Chamsaz M. Hyperbranched polyglycerol/graphene oxide nanocomposite reinforced hollow fiber solid/liquid phase microextraction for measurement of ibuprofen and naproxen in hair and waste water samples. J Chromatogr B Analyt Technol Biomed Life Sci 2016; 1029-1030: 81-7.
[http://dx.doi.org/10.1016/j.jchromb.2016.07.010] [PMID: 27428449]
[41]
Forough M, Farhadi K, Molaei R, et al. Capillary electrophoresis with online stacking in combination with AgNPs@MCM-41 reinforced hollow fiber solid-liquid phase microextraction for quantitative analysis of Capecitabine and its main metabolite 5-Fluorouracil in plasma samples isolated from cancer patients. J Chromatogr B Analyt Technol Biomed Life Sci 2017; 1040: 22-37.
[http://dx.doi.org/10.1016/j.jchromb.2016.11.025] [PMID: 27898365]
[42]
Song X-Y, Shi Y-P, Chen J. A novel extraction technique based on carbon nanotubes reinforced hollow fiber solid/liquid microextraction for the measurement of piroxicam and diclofenac combined with high performance liquid chromatography. Talanta 2012; 100: 153-61.
[http://dx.doi.org/10.1016/j.talanta.2012.08.042] [PMID: 23141323]
[43]
Al-Hashimi N, Shahin R, AL-Hashimi A, Al Ajeal A, Tahtamouni L, Basheer C. Cetyl-alcohol-reinforced hollow fiber solid/ liquid-phase microextraction and HPLC-DAD analysis of ezetimibe and simvastatin in human plasma and urine. Biomed Chromatogr 2019; 33: 1-8.
[44]
Al-Hashimi NN, El-Sheikh AH, Qawariq RF, Shtaiwi MH, AlEjielat R. Multi-walled carbon nanotubes reinforced into hollow fiber by chitosan sol-gel for solid/liquid phase microextraction of NSAIDs from urine prior to HPLC-DAD analysis. Curr Pharm Biotechnol 2019; 20(5): 390-400.
[http://dx.doi.org/10.2174/1389201020666190405181234] [PMID: 30961482]
[45]
Ajinkya N, Yu X, Kaithal P, Luo H, Somani P, Ramakrishna S. Magnetic iron oxide nanoparticle (IONP) synthesis to applications: present and future. Materials (Basel) 2020; 13(20): 1-35.
[http://dx.doi.org/10.3390/ma13204644] [PMID: 33080937]
[46]
Siddiqi KS, Ur Rahman A, Tajuddin , Husen A. Biogenic fabrication of iron/iron oxide nanoparticles and their application. Nanoscale Res Lett 2016; 11(1): 498.
[http://dx.doi.org/10.1186/s11671-016-1714-0] [PMID: 27837567]
[47]
Yildiz I. Application of magnetic nanoparticles in biomedical separation and purification. Nanotechnol Rev 2015; 5(3): 331-40.
[48]
Fan C, Liang Y, Dong H, et al. In-situ ionic liquid dispersive liquid-liquid microextraction using a new anion-exchange reagent combined Fe3O4 magnetic nanoparticles for determination of pyrethroid pesticides in water samples. Anal Chim Acta 2017; 975: 20-9.
[http://dx.doi.org/10.1016/j.aca.2017.04.036] [PMID: 28552303]
[49]
Shtaiwi M, Tahboub D, El-Sheikh A, El-Hashimi N. Magnetic solid-phase extraction of metal ions: comparison of adding Schiff base to the extraction medium vs. magnetite modification with Schiff base. J Environ Chem Eng 2020; 8: 1-10.
[http://dx.doi.org/10.1016/j.jece.2020.103675]
[50]
Zhao Q, Wei F, Xiao N, Yu Q-W, Yuan B-F, Feng YQ. Dispersive microextraction based on water-coated Fe3O4 followed by gas chromatography-mass spectrometry for determination of 3- monochloropropane-1,2-diol in edible oils. J Chromatogr A 2012; 1240: 45-51.
[http://dx.doi.org/10.1016/j.chroma.2012.03.090] [PMID: 22520640]
[51]
Ganapathe L, Mohamed M, Yunus R, Berhanuddin D. Magnetite (Fe3O4) nanoparticles in biomedical application: from synthesis to surface functionalization. Magnetochemistry 2020; 6(68): 1-35.
[http://dx.doi.org/10.3390/magnetochemistry6040068]
[52]
Katz E. Synthesis, properties and application of magnetic nanoparticles and nanowires- a brief introduction. Magnetochemistry 2019; 5(61): 1-15.
[http://dx.doi.org/10.3390/magnetochemistry5040061]
[53]
Beveridge JS, Stephens JR, Williams ME. The use of magnetic nanoparticles in analytical chemistry. Annu Rev Anal Chem (Palo Alto, Calif) 2011; 4(1): 251-73.
[http://dx.doi.org/10.1146/annurev-anchem-061010-114041] [PMID: 21417723]
[54]
Sandler SE, Fellows B, Mefford OT. Best practices for characterization of magnetic nanoparticles for biomedical applications. Anal Chem 2019; 91(22): 14159-69.
[http://dx.doi.org/10.1021/acs.analchem.9b03518] [PMID: 31566353]
[55]
Moacă E-A, Mihali C-V, Macaşoi I-G, et al. Fe3O4@C matrix with tailorable adsorption capacities for paracetamol and acetylsalicylic acid: Synthesis, characterization, and kinetic modeling. Molecules 2019; 24(9): 1-18.
[http://dx.doi.org/10.3390/molecules24091727] [PMID: 31058855]
[56]
Xu J-K, Zhang F-F, Sun J-J, Sheng J, Wang F, Sun M. Bio and nanomaterials based on Fe3O4. Molecules 2014; 19(12): 21506-28.
[http://dx.doi.org/10.3390/molecules191221506] [PMID: 25532846]
[57]
Eś’haghi Z, Esmaeili-Shahri E. Sol-gel-derived magnetic SiO2/TiO2 nanocomposite reinforced hollow fiber-solid phase microextraction for enrichment of non-steroidal anti-inflammatory drugs from human hair prior to high performance liquid chromatography. J Chromatogr B Analyt Technol Biomed Life Sci 2014; 973C: 142-51.
[http://dx.doi.org/10.1016/j.jchromb.2014.09.030] [PMID: 25464107]
[58]
Arévalo P, Isasi J, Caballero A, Marco J, Martín-Hernández F. Magnetic and structural studies of Fe3O4 nanoparticles synthesized via coprecipitation and dispersed in different surfactants. Ceram Int 2017; 43(13): 10333-40.
[http://dx.doi.org/10.1016/j.ceramint.2017.05.064]
[59]
Hein H, Pramanik C, Heinz O, et al. Nanoparticle decoration with surfactants: molecular interactions, assembly, and applications. Surf Sci Rep 2017; 72: 1-58.
[http://dx.doi.org/10.1016/j.surfrep.2017.02.001]
[60]
Roth H-C, Schwaminger S, García P, Ritscher J, Berensmeier S. Oleate coating of iron oxide nanoparticles in aqueous systems: The role of temperature and surfactant concentration. J Nanopart Res 2016; 18(4): 1-12.
[http://dx.doi.org/10.1007/s11051-016-3405-2]
[61]
Guerrini L, Alvarez-Puebla RA, Pazos-Perez N. Surface modification of nanoparticles for stability in biological fluids. Materials (Basel) 2018; 11(7): 1-28.
[http://dx.doi.org/10.3390/ma11071154] [PMID: 29986436]
[62]
Reza R, Pérez C, González R, Romero H, Casillas P. Effect of the polymeric coating over Fe3O4 particles used for magnetic separation. Cent Eur J Chem 2010; 8(5): 1041-6.
[63]
Wang C, Wang Y, Ouyang Z, Shen T, Wang X. Preparation and characterization of polymer-coated Fe3O4 magnetic flocculant. Sep Sci Technol 2018; 53(5): 814-22.
[http://dx.doi.org/10.1080/01496395.2017.1404613]
[64]
Tajodini N, Karimnezhad K, Moghimi A. Alternative method of extraction of ultra-trace Co(II) with disks of octadecyl silica membrane modified nano-Fe3O4-encapsulated-dioctyl phthalate and linked-diethylenetriamine. Eur J Clin Med 2021; 8(1): 2080-8.
[65]
Mahmoud M, Yakout A, Hussein K, Osman M. Magnetic accumulation and extraction of Cd(II), Hg(II) and Pb(II) by a novel nano-Fe3O4-coated-dioctylphthalate-immobilized-hydroxylamine. J Environ Chem Eng 2015; 3: 843-51.
[http://dx.doi.org/10.1016/j.jece.2015.03.024]
[66]
Aydın M, Durmus Z, Kavas H, et al. Synthesis and characterization of poly(3-thiophene acetic acid)/Fe3O4 nanocomposite. Polyhedron 2011; 30: 1120-6.
[http://dx.doi.org/10.1016/j.poly.2011.01.009]
[67]
Farokhia A, Hosseini-Monfareda H. A recyclable Mn-porphyrin in catalyst for enantioselective epoxidation of unfunctionalized olefins using molecular dioxygen. New J Chem 2016; 40: 5032-43.
[http://dx.doi.org/10.1039/C6NJ00808A]
[68]
Smallwood IM. Handbook of organic solvent properties. 1st ed. London, UK: Amold, Hodder Headline Group 1996.
[69]
Rezaee M, Assadi Y, Milani Hosseini MR, Aghaee E, Ahmadi F, Berijani S. Determination of organic compounds in water using dispersive liquid-liquid microextraction. J Chromatogr A 2006; 1116(1-2): 1-9.
[http://dx.doi.org/10.1016/j.chroma.2006.03.007] [PMID: 16574135]
[70]
Belter M, Sajnóg A, Barałkiewicz D. Over a century of detection and quantification capabilities in analytical chemistry- historical overview and trends. Talanta 2014; 129: 606-16.
[http://dx.doi.org/10.1016/j.talanta.2014.05.018] [PMID: 25127640]
[71]
Peng J, Tian H, Du Q, Hui X, He H. A regenerable sorbent composed of a zeolite imidazolate framework (ZIF-8), Fe3O4 and graphene oxide for enrichment of atorvastatin and simvastatin prior to their determination by HPLC. Mikrochim Acta 2018; 185(2): 141.
[http://dx.doi.org/10.1007/s00604-018-2697-6] [PMID: 29594811]
[72]
Tajabadi F, Ghambarian M, Yamini Y. Evaluation of three-phase hollow fiber microextraction based on two immiscible solvents coupled to GC and HPLC for determination of statin drugs in biological fluids. Anal Methods 2015; 7: 2959-67.
[http://dx.doi.org/10.1039/C4AY02980A]
[73]
Panahi HA, Chabouk M, Ejlali M. Hollow-fiber-supported liquid membrane microextraction of amlodipine and atorvastatin. J Sep Sci 2014; 37(15): 2018-24.
[http://dx.doi.org/10.1002/jssc.201400138] [PMID: 24833551]
[74]
Panahi H, Feizbakhsh A, Karimpour M, Moniri E. Determination of gemfibrozil in drug matrix and human biological fluid by dispersive liquid-liquid microextraction with high performance liquid chromatography. Yao Wu Shi Pin Fen Xi 2013; 21: 109-14.
[75]
Ardila J, Oliveira G, Medeiros R, Fatibello-Filho O. Determination of gemfibrozil in pharmaceutical and urine samples by square-wave adsorption stripping voltammetry using a glassy carbon electrode modified with multi-walled carbon nanotubes within a dihexadecyl hydrogen. J Electroanal Chem (Lausanne) 2013; 690: 32-7.
[http://dx.doi.org/10.1016/j.jelechem.2012.11.038]

Rights & Permissions Print Cite
Article Metrics
11
1
© 2024 Bentham Science Publishers | Privacy Policy